The aim of this study was to investigate the methods of conception and delivery, as well as the course and outcome of 42 pregnancies occurring in 15 female patients (27 pregnancies) and partners of 8 male patients (15 pregnancies) with β-thalassemia major who were successfully treated with allogeneic hematopoietic cell transplantation (HCT). Most pregnancies (n = 21) were achieved with spontaneous conception in female patients. There were two miscarriages. Five pregnancies were late preterm. Delivery was vaginal in 4 cases and by caesarean section in 18. Overall, 22 term pregnancies resulted in successful deliveries of 23 neonates. Two of 23 neonates were symmetrical small for gestational age / intrauterine growth restriction. All 15 pregnancies that occurred in partners of men who received an allogeneic HCT were achieved with spontaneous conception. No miscarriage was observed. Overall, 14 term pregnancies resulted in successful deliveries of 14 live-born singletons. Delivery was vaginal in nine cases and by caesarean section in five. All infants were full-term. Many patients with β-thalassemia major who received an allogeneic HCT retained or recovered their fertility after transplant. In these patients, pregnancy has been a practical and safe possibility and usually had a favorable outcome as in the normal population.
INTRODUCTION β-thalassemia major, also called Cooley anemia, is a severe transfusion-dependent anemia whose treatment includes regular RBC transfusions, iron chelation and management of secondary complications due to iron overload. 1 Despite the excellent results obtained in the last three decades with the transfusion policy and iron chelation, complications are not infrequent. The hypogonadism was the most frequent complication, affecting 54.7% of the patients. 2 In women the commonest abnormality is hypogonadotropic hypogonadism, which presents with primary amenorrhea, delayed puberty or secondary amenorrhea with consequent infertility. 3 Oligospermia and asthenospermia affect more than one-half of men with β-thalassemia major. 4 The endocrine complications are directly related to the serum ferritin level. 5 Successful pregnancies in women and partners of men treated with conservative therapy for thalassemia major have been reported. [6] [7] [8] Hematopoietic cell transplantation (HCT) is the only definitive cure currently available for patients with β-thalassemia major who have a related or unrelated HLA identical donor. 9 In 2008, we described the long-term results of survival in patients with thalassemia major treated with HCT in our center. The 20-year probability of overall survival and disease-free survival was 89.2% and 85.7%, respectively. Ninety-nine patients out of 103 survivors (86%) were definitively cured after a median follow-up of 15 years (range, . 10 The aim of the present study was to investigate the methods of conception and delivery, as well as the course and outcome of 42 post-transplant pregnancies occurring in 15 female patients and partners of 8 male patients with β-thalassemia major who were successfully treated with allogeneic HCT in our center.
PATIENTS AND METHODS
Between May 1983 and April 2006, 115 consecutive patients (males 57) with thalassemia major were treated with HCT in Pescara. The study was approved by the local institutional review board. Informed consent for the transplant was obtained from all patients and donors or their legal guardians in accordance with the Declaration of Helsinki. Details about the patient's and donor's clinical characteristics, as well as the transplant protocol have been described elsewhere. 10, 11 Each recipient of marrow transplantation was given unique patient number (UPN). Briefly, all patients were given busulfan (total dose, 14 mg/kg) and cyclophosphamide (total dose, 200 mg/kg) as conditioning therapy and cyclosporine and short-course methotrexate as GvHD prophylaxis. The transplantrelated mortality at 1 year was 8.7%. The 20-year Kaplan-Meyer estimate of disease-free survival was 85.7%. HCT was successful with definitive cure in 99 patients. As of 21 February 2016, 24 patients were lost to follow-up and 75 (38 males, 37 females) were living and cured after a median follow-up of 24 years (range, 10-33). Among this patient population, 15 females (40%) and 8 partners of males (21%) became pregnant. Table 1 shows clinical characteristics of patients at transplantation. Sustained and complete engraftment of donor cells was documented in 14 of 15 patients and resulted in definitive cure with a median hemoglobin level of 12.5 g/dL (range, 10.8-13.5). Acute GvHD affected three patients (grade I in 1, grade II in 1 and grade III in 1). Chronic GvHD affected two patients in a moderate intensity. Nine patients were treated with regular phlebotomy program for 12 months in order to reduce iron overload. No other iron chelation therapy was used in the other patients. At the time of transplantation, nine patients were prepuberal, four were puberal and two were puberal with primary amenorrhea (Table 2) . Regular menses occurred spontaneously or were induced with hormone replacement in six and nine patients, respectively, post transplant at a median age of 17 years (range, 13-28). Table 3 shows the methods of conception as well as the outcome of 27 pregnancies that occurred in 15 women. Their median age at first conception was 31 years (range, 21-46). The partner's median age was 33 years (range, 27-39). Two partners were carriers of β-thalassemia trait and one was affected by thalassodrepanocytosis.
RESULTS

Women who became pregnant
Twenty-one pregnancies (78%) were achieved with spontaneous conception in 11 women. Six pregnancies were achieved in four women following gonadotrophin-induced ovulation, fertilization in vitro and embryo transfer in two and heterologous ovodonation in two women, respectively. The median time elapsed after HCT before a woman got pregnant was 19 years (10-26). There were two miscarriages (7.4%) due to ectopic pregnancy in one case and placental abnormality in the other case, one miscarriage due to accidental cause (unintentional) and two induced abortions for personal reasons. Two pregnancies were bigeminal. One of them (UPN 278) resulted in two normal twins. The other bigeminal pregnancy (UPN 90) was complicated with the intrauterine death of one fetus in the 12th week of gestation and resulted in one normal live birth. Overall, 22 term pregnancies resulted in successful deliveries of 23 neonates, 21 live-born singletons and 1 set of twins. The pregnancy outcome was uncomplicated in 9 cases (41%) and was complicated by several conditions in the remaining 13 cases (59%) ( Table 3 ). The median duration of gestation was 38 weeks (range, 35-40). Five pregnancies (22.7%) were late preterm with gestation duration of 35-36.6 weeks. Delivery was vaginal in 4 cases (18%) and by caesarean section in 18 (82%). Reasons for caesarean section are shown in Table 3 . There was no delivery-related complication in the mothers.
Neonates
Seventeen infants were full-term and 6 (26%) were preterm, defined by birth at 34(0/7) through 36(6/7) weeks' gestation ( Table 4 ). The preterm deliveries occurred in 4 of 15 women (26.6%). Two of them have conceived by medical-assisted reproductive procedures. The median birth weight of the 23 neonates was 2.950 kg (range, 1.990-4.200 kg). Two of them (8.7%) were small for gestational age (SGA) (percentile o 10th), 17 (73.9%) were adequate for gestational age (percentile 10-90th) and 4 (17.4%) were large for gestational age (LGA) (490th percentile). The median birth height was 49 cm (range, 44-54 cm). Two neonates (8.7%) were SGA, 16 (69.6%) were adequate for gestational age and 5 (21.7%) were LGA. Overall, 2 of 23 neonates (8.7%) were symmetrical SGA/intrauterine growth restriction and 1 (4.3%) was symmetrical large (LGA/intrauterine growth restriction). Both children recovered normal weight in the 6 months post delivery. One newborn showed a respiratory distress syndrome with an Apgar index of 6 at delivery and 10 at 5 min. The Apgar index was 9 in one newborn baby and 10 in the remaining 21. No other newborn complication was registered. Of relevance, considering the history of RBC transfusions before transplant, no immunohematologic complication was observed neither in the mothers during pregnancy nor in the infants at birth. None of the neonates had any congenital malformation.
Although 12 out of 15 patients were hepatitis C virus (HCV)-positive and 4 of them showed high levels of HCV RNA viral load at the beginning of gestation, the serum aminotransferase levels were persistently in the normal range in 10 out of 12 cases. Two patients showed a moderate increase of serum aminotransferase levels in the second and third trimester with subsequent return to normal levels in the postpartum period. No significant fluctuation of HCV RNA viral load was observed in the affected individuals during pregnancy. Of relevance, none of the 19 children born from HCV-infected mothers were found to be infected after Abbreviations: HBV = hepatitis B virus; HCT = hemopoietic cell transplantation; HCV = hepatitis C virus. Abbreviations: HCT = hemopoietic cell transplantation; UPN = unique patient number.
Pregnancy outcome after HCT for thalassemia major S Santarone et al testing for both HCV antibodies and RNA at 3, 6 and 12 months of life. Breast-feeding was started in 15 out of 23 neonates (65%) and was continued for more than 3 months in 12 of them. All 23 children showed regular growth and development after a median follow-up of 5 years (range, 1 month to 14 years). In the same period, all women showed normal hemoglobin levels.
Two children were diagnosed with Cooley disease at 3 months of age due to the β-thalassemia trait present in the father. In both cases chorionic villous sampling was done in the first trimester of Abbreviations: F = female; GA = gestational age; HCT = hemopoietic cell transplantation; M = male; UPN = unique patient number.
Pregnancy outcome after HCT for thalassemia major S Santarone et al gestation and showed the presence of thalassemia major in the fetus. These two children received a successful allogeneic HCT from an unrelated-matched donor and are living and doing well at 7 and 2 years post transplant, respectively. Another child was diagnosed with thalassodrepanocytosis and is doing well with moderate anemia at 4 years of age. The diagnosis was previously done during the first trimester of gestation by amniocentesis technique.
Men who fathered a child Table 1 shows clinical characteristics at transplantation of eight patients who fathered a child. Sustained and complete engraftment of donor cells was documented in all patients with definitive cure. Acute GvHD was present in four patients (grade II in all cases). Chronic GvHD affected three patients in a mild intensity. Three patients were treated with regular phlebotomy program for 12 months in order to reduce iron overload. No other iron chelation therapy was used in the other patients. At the time of transplantation, four patients were prepuberal and four were puberal. Table 5 shows the outcome of 15 pregnancies that occurred in 8 women. The median age of the eight women who became pregnant was 27 years (range, 24-34) at first conception. None of them were affected by thalassemia trait or by any other disease. The patient's median age at first conception was 30 years (range, 24-39). All 15 pregnancies were achieved with spontaneous conception. There was one induced abortion for personal reasons. Overall, 14 term pregnancies resulted in successful deliveries of 14 live-born singletons. The pregnancy outcome was uncomplicated in all cases. The median duration of gestation was 38 weeks (range, 37-40). Delivery was vaginal in 9 cases (64%) and by caesarean section in 5 (36%). Reasons for caesarean section are shown in Table 5 . There was no delivery-related complication in the mothers.
Neonates All infants were full-term (Table 6 ). The median birth weight of the 14 neonates was 3.330 kg (range, 3.240-3.870 kg). According to weight, none of them was SGA, 12 (85.7%) were adequate for gestational age and 2 (14.3%) were LGA. The median birth height was 51 cm (range, 49-53 cm). According to height, none of them was SGA, 9 (64.3%) were adequate for gestational age and 5 (35.7%) were LGA. Overall, there was only one infant (7.1%) who was LGA/intrauterine growth restriction. No neonatal complication was evident. The Apgar index was 10 at delivery in all cases. None of the neonates had any congenital malformation. Although six out of eight patients were HCV-positive and three of them showed high levels of HCV RNA viral load at the time of conception, no partner of these patients or their children were infected with HCV. Abbreviations: F = female; GA = gestational age; HCT = hemopoietic cell transplantation; M = male; UPN = unique patient number.
Pregnancy outcome after HCT for thalassemia major S Santarone et al Breast-feeding was started in 13 out of 14 neonates (93%) and was continued for more than 3 months in 12 of them. One child showed mild cognitive impairment at 12 months and is now receiving psychoeducational rehabilitation. The remaining 13 children showed regular growth and development after a median follow-up of 7 years (range, 2 months to 22 years).
DISCUSSION
Despite major advances in the management of patients affected by transfusion-dependent thalassemia major, pregnancies and fatherhood are still relatively uncommon for affected individuals. Since an early report of a successful pregnancy in a woman with thalassemia major by Walker et al. 12 other successful pregnancies have been described in the literature. 13 The prevalence of fetal and maternal complications has been reported to be higher as compared with that observed in the general population. 14, 15 Successful pregnancies in women and partners of man who underwent either an allogeneic or autologous HCT for hematological malignancies are well documented, as are deliveries of normal children. [16] [17] [18] Pregnancies following allogeneic HCT have been reported only in occasional patients transplanted for thalassemia major. Patients who received an allogeneic HCT are at increased risk of gonadal insufficiency and reduced fertility because of both the effects of transfusional iron overload and the gonadotoxic effects of drugs used in the conditioning regimen. This condition could represent a deterrent to embark on pregnancy. In this study we report on 42 pregnancies in ex-thalassemic patients (15 women and partners of 8 males). We cannot estimate the fertility after HCT as it was not possible to determine precisely what proportion of patients had attempted to have children.
As expected, partners of male transplanted patients had uncomplicated pregnancies considering that all of them were normal women without any physical condition at risk. Conception was spontaneous and natural in all cases and was followed by uncomplicated outcome with normal gestational age and no miscarriage. Frequency (29%) and causes of cesarean section were similar to those observed in the normal population. No deliveryrelated complication was observed in the mothers or in the newborns. All surviving offspring developed normally with the exception of one child who showed mild cognitive impairment, now receiving appropriate psychoeducational treatment.
On the other hand, transplanted thalassemic women became pregnant in a remarkably high proportion of cases, but their fertility profile reflected that they had been exposed both to the consequences of the pre-transplant iron overload and to the action of alkylating and immunosuppressive drugs used as preparation for marrow transplantation in the conditioning regimen. Our report indicates that an increasing number of women who received an allogeneic transplant for thalassemia may have a successful pregnancy, but often they require ovarian stimulation. This remains a concern considering that 9 of 15 patients (60%) needed post-transplant hormonal supplementation to restore normal menses. In our study, 15 out of 37 female patients (40%) became pregnant. Twenty-one pregnancies (78%) were achieved with spontaneous conception in 11 women. Six pregnancies were achieved in four women following either fertilization in vitro and embryo transfer or heterologous ovodonation. These pregnancies were included in the analysis in order to evaluate the outcome of pregnancy. The rate of miscarriage was 2 (7.4%), which is similar either to that observed for patients with malignant disease who received TBI as conditioning therapy (8.3%) or for patients with severe aplastic anemia who received cyclophosphamide as preparative regimen (7.1%). 18 In addition to these two cases of miscarriage, in general, the rate of complications was rather high (59%), although medical treatment was successful in all cases. One patient, who showed mixed chimerism post transplant with low levels of hemoglobin (8.5 g/dL), required RBC support for her two pregnancies both during the last 2 months of pregnancy and at delivery. Of relevance, cardiac function was not impaired during pregnancy and this can be explained by the normal cardiac status before pregnancy in all patients.
We noted a remarkably higher (22.7%) than normal rate of preterm delivery (9.1% in the US report). 19 This complication has been described in women who had received TBI in their pretransplant conditioning, and, in particular, in those who had conceived by medically assisted reproductive techniques. Indeed, two of the four women who showed preterm delivery underwent fertilization in vitro and embryo transfer or an heterologous ovodonation. None of them had either acute or chronic GvHD. In any case, disorders of implantation might underlie intrauterine growth retardation and premature birth. The drugs used in the conditioning therapy (busulfan and cyclophosphamide) might have contributed to cause disorders of implantation. 20 In general, there was no influence of the time elapsed after HCT on the outcome of pregnancies.
Another noteworthy feature of our study is the large proportion of pregnancies that have been concluded with caesarean section. Delivery by caesarean section was observed in 18 of 22 pregnancies (82%). Similar frequency has been described in 58 pregnancies observed in 52 women affected by thalassemia major and treated with transfusions and iron chelation. In this study, caesarean section was used as the method of delivery in 52 of 58 pregnancies (90%). 8 Lower frequency of caesarean section has been reported by Salooja et al. 18 in allograft patients. In this study, caesarean section has been used in 6 of 12 (50%) of pregnancies in patients affected by malignant disease and treated with TBI, and in 15 of 55 (33%) of pregnancies in patients affected by aplastic anemia and treated with cyclophosphamide.
The present study contributes to answering some important questions about HCV infection, namely, the impact of pregnancy on maternal HCV disease, the impact of HCV infection on pregnancy and delivery, the risk of sexual transmission of HCV infection and the risk of mother-to-child HCV transmission. All these questions have been recently well reviewed by Tosone et al. 21 Regarding the first point, there was no particular exacerbation of chronic HCV disease in the 12 affected women who became pregnant both during pregnancy or in the postpartum period. Very few studies have investigated the impact of maternal HCV infection on pregnancy outcome and delivery. The data available indicate an increased risk of gestational diabetes, premature membrane rupture, an increased rate of caesarean delivery, higher rates of preterm delivery, placental abruption, low birth weight, prematurity, low Apgar score at 1 min, increased neonatal jaundice, congenital malformations and newborn perinatal mortality. In our small series of 12 HCV-infected women, we can speculate that HCV infection might have a role in high rate of caesarean section and in the rate of preterm delivery. In our study, none of the six women of HCV-positive partners showed evidence of HCV infection. This is not surprising because the sexual contact is considered an inefficient mode of HCV spread. Several studies have reported a low rate o5% of HCV transmission in heterosexual couples. 22 Numerous studies have evaluated the risk of mother-to-child HCV transmission (vertical transmission) with conflicting results. In fact, the rates of transmission varied from 0 to 30%. 23, 24 Fortunately, in our study none of the 19 children born from HCV-infected mothers were affected by HCV transmission.
In summary, although patients with thalassemia major are usually rendered permanently infertile following allogeneic HCT both as consequence of previous iron overload or the gonadal injury due to the alkylating drugs used in the conditioning regimen, many patients retained or recovered their fertility. In these patients pregnancy has been a practicable and manageable possibility with a generally favorable outcome comparable to the normal population. They necessitate very careful assessment of the advisability of pregnancy and close health monitoring during and after each pregnancy by a multidisciplinary team, which must include a genetic counseling.
